N2OFF
Develops mitochondrial transporter drug candidates and European solar and storage projects.
Something off on this page? Send us feedback.
Profile
Uses MITOLINE™ to discover drug candidates for mitochondrial transport proteins while developing European solar and battery-storage projects. Both reportable segments remain pre-revenue, with biotechnology at a preclinical stage and projects intended for sale or longer-term operation.
Uses MITOLINE™ to model mitochondrial membrane transport proteins and screen molecules for drug candidates. The biotechnology activity, conducted through wholly owned MitoCareX Bio in Ness Ziona, focuses on an undisclosed transporter in cancers and inflammatory metabolic diseases. Its discovery work has selected a hit compound for hit-to-lead medicinal chemistry, but has no approved products, completed preclinical or clinical trials, product revenue, or sales capability.
Develops solar and battery-storage projects in Europe through NITO Renewable Energy and Solterra-related arrangements. The renewable model contemplates selling projects as they advance from land identification and development through construction, while potentially retaining some for longer-term operation.
Both reportable segments remain pre-revenue. The biotechnology activity has no manufacturing facility and would depend on third-party manufacturers if a candidate advances.
Company facts
Key statistics
Year to date −81.9% · Average volume (30d) 66.8K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | — | −$25.96 | — | — | — | — | +5.98% |
| May 14, 2026Q1 FY26 | — | −$12.10 | — | — | — | — | −3.88% |
| Nov 13, 2025Q3 FY25 | — | −$8.29 | — | — | $2.0K | — | — |
| Nov 14, 2024Q3 FY24 | — | −$12.91 | — | — | $9.0K | — | — |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $66.0K | $0 | $2.0K | −$68.0K | $0 | $0 | |
| Gross profit | $52.0K | −$2.0K | −$3.0K | −$68.0K | $0 | −$106.0K | |
| Operating income | −$619.0K | −$2.8M | −$1.3M | −$587.0K | −$8.2M | −$1.6M | |
| Net income | −$1.2M | −$4.5M | $429.0K | $1.3M | −$6.6M | −$11.1M | |
| Diluted EPS | −$2.58 | −$6.40 | $0.45 | $0.00 | −$10.74 | −$13.66 | |
| Gross margin | 78.8% | — | -150.0% | — | — | — | |
| Operating margin | -937.9% | — | -66,300.0% | — | — | — |
Fiscal years (4-quarter sums)FY21 $438.1K · FY22 $394.0K · FY23 $263.4K · FY24 $210.4K · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $8.9M · Total debt $426.0K · Total assets $18.7M · Shareholders' equity $1.9M
Dividends
No dividends on record.
Ownership
Shares outstanding 56.6K · Float 23.4K
Insiders — no current Form 4 position.
This issuer lists more than one class and the share count spans them all, so a stake here reads as a share of the whole company, not of this class.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jan 29, 2026 | Eun Young Lee | 10 percent owner | −127 | $1.36 |
Peers
- Relay Therapeutics
Computational–experimental small-molecule discovery platform rival.
- Schrödinger
Physics-plus-AI molecular discovery platform rival.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| N2OFF | $1.78 | −3.26% | $104.1K | — | — | — | −77.8% |
| Relay Therapeutics | $19.10 | +1.82% | $4.11B | — | — | 397.4 | −48.3% |
| Schrödinger | $19.67 | −0.15% | $1.47B | — | — | 5.7 | +7.5% |
| Median | — | — | 201.6 | −20.4% |